Sarepta Therapeutics and Roche are looking to get approval to continue clinical trials of their Duchenne muscular dystrophy ...

Roche, the company to which the treatment is licensed outside ... a gene therapy for ambulatory patients aged 3-7 years old ...

Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...

Roche, the company to which the treatment is ... HC Wainwright upgraded Sarepta on Wednesday from Sell to Neutral, saying it is trading within a fair range. Analyst Mitchell S.

Sarepta Therapeutics (NASDAQ:SRPT) stock draws an Overweight rating at Wells Fargo, based on commercial prospects for ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in ...

Sarepta and Roche paused multiple Elevidys trials in the EU at the EMA’s request. HC Wainwright upgraded Sarepta to Neutral but sees Elevidys sales falling by Q2 2025. In a market dominated by ...

Roche (RHHBY) sent a letter dated March 31 to the World Duchenne Organization stating the European Medicines Agency requested a temporary ...